ACKR2 Antibody

What is ACKR2 and why is it important to study?

ACKR2 (also known as D6, CCR10, CCBP2) is an atypical chemokine receptor that functions distinctly from conventional chemokine receptors. It serves as a pivotal regulator of chemokine-driven inflammatory responses by binding, internalizing, and degrading inflammatory CC-chemokines . ACKR2 displays remarkable promiscuity in ligand binding, capable of interacting with up to 14 different inflammatory CC-chemokines, including CCL2, CCL4, CCL5, and even CXCL10 .

This receptor plays a crucial role in fine-tuning inflammatory responses by acting as a scavenger that removes excessive chemokines from the microenvironment. Recent studies have highlighted its importance in regulating immune cell infiltration in tumors, suggesting therapeutic potential in cancer immunotherapy . Additionally, ACKR2 has been implicated in regulating neovascularization during inflammatory conditions such as herpes stromal keratitis .

What are the key structural features of ACKR2 relevant for antibody design?

The N-terminal region of ACKR2 contains a critical conserved tyrosine motif that is essential for ligand binding, internalization, and chemokine scavenging functions . Post-translational sulfation of this tyrosine motif significantly contributes to the receptor's ability to internalize ligands . In fact, studies have demonstrated that peptides derived from this N-terminal region can bind inflammatory chemokines and inhibit their interaction with signaling receptors, but only when in the sulfated form .

What detection methods are most effective when using ACKR2 antibodies?

Multiple detection methods have proven effective for ACKR2 antibody applications:

• Immunohistochemistry (IHC): Widely used for detecting ACKR2 expression in tissue sections, allowing visualization of receptor distribution across different cell types .

• Flow cytometry: Effective for quantifying ACKR2 expression on cell surfaces and for studying internalization dynamics. Protocols typically involve using either direct fluorophore-conjugated ACKR2 antibodies or biotinylated antibodies with fluorophore-conjugated secondary detection reagents .

• Western blotting: Useful for detecting ACKR2 protein levels and identifying post-translationally modified variants. When performing Western blots, researchers should be aware that ACKR2 may appear as multiple bands due to glycosylation states .

• ELISA: Suitable for quantitative measurement of soluble ACKR2 in biological fluids or cell culture supernatants .

For optimal results, antibody validation through ACKR2 knockout controls or competitive blocking with recombinant ACKR2 is strongly recommended to confirm specificity.

How can ACKR2 antibodies be used to study receptor internalization and chemokine scavenging?

To study ACKR2's chemokine scavenging function, researchers can employ chemokine uptake assays with fluorescently-labeled chemokines. In these assays, ACKR2-expressing cells are incubated with labeled chemokines (e.g., Alexa-CCL22 or Alexa-CCL2), and internalization is measured by flow cytometry .

A methodological approach involves:

• Transfecting cells with ACKR2 expression constructs (wild-type or mutant variants)

• Incubating cells with fluorescently-labeled chemokines (60-100 ng/well is typical)

• Comparing uptake between wild-type and mutant ACKR2 or between antibody-blocked and unblocked receptors

• Quantifying internalization by flow cytometry

To specifically assess the role of antibodies in blocking scavenging, ACKR2 antibodies can be pre-incubated with cells before adding labeled chemokines. Alternatively, competition assays can be performed using ACKR2-N terminal peptides that mimic the receptor's binding domain .

For advanced studies, researchers can combine antibody detection with siRNA knockdown of sulfation enzymes (TPST-1 and TPST-2) to investigate how post-translational modifications affect receptor function and antibody binding .

What considerations are important when using ACKR2 antibodies in cancer immunotherapy research?

Recent research highlights ACKR2 as a promising target for cancer immunotherapy, particularly for enhancing response to immune checkpoint blockade (ICB) . When designing experiments in this area, researchers should consider:

• Tumor microenvironment assessment: Use ACKR2 antibodies in multiplex immunofluorescence to correlate receptor expression with immune infiltrate composition. Data from melanoma patients in The Cancer Genome Atlas revealed that patients with high levels of chemokines scavenged by ACKR2 had better survival rates, with increased expression of NK and CD8 T cell markers .

• Mechanistic studies: When targeting ACKR2 (via genetic knockout or antibody neutralization), monitor changes in:

  • Chemokine levels (particularly CCL5 and CXCL10) in the tumor microenvironment

  • Infiltration of cytotoxic immune cells (NK cells, CD8+ T cells)

  • Expression of activation markers (e.g., CD69) on infiltrating lymphocytes

• Combination therapy assessment: When evaluating ACKR2 targeting in combination with ICB (e.g., anti-PD-1), use ACKR2 antibodies to confirm target engagement and monitor changes in the tumor immune contexture .

• Blocking experiments: Include anti-chemokine blocking antibodies (e.g., anti-CCL5) to validate that observed effects are mediated through the chemokine scavenging function of ACKR2 .

What methodological approaches can address challenges in ACKR2 antibody specificity?

Ensuring antibody specificity is critical for ACKR2 research. Several approaches can help validate specificity:

• Genetic controls: Compare antibody staining between wild-type and ACKR2 knockout samples. This represents the gold standard for validation .

• Epitope-tagged constructs: Use epitope-tagged ACKR2 (e.g., HA-ACKR2) alongside commercial anti-ACKR2 antibodies to confirm detection of the same protein. This approach has been effectively used in transfection studies .

• Peptide competition: Pre-incubate antibodies with synthetic ACKR2 peptides corresponding to the immunogen sequence to block specific binding.

• Multiple antibody concordance: Use antibodies targeting different epitopes of ACKR2 and verify concordant results.

• Correlation with mRNA expression: Compare protein detection with quantitative PCR results for ACKR2 mRNA. Primers can target specific regions (5′-AGGAAGGATGCAGTGGTGTC-3′ and 5′-CGGAGCAAGACCATGAGAAG-3′) .

When interpreting results, be aware that post-translational modifications, particularly tyrosine sulfation, can affect epitope accessibility and antibody binding .

How can ACKR2 antibodies be utilized in studying post-translational modifications?

Post-translational modifications, particularly sulfation of N-terminal tyrosines, are critical for ACKR2 function. To study these modifications:

• Combined siRNA and antibody approaches: Transfect cells with siRNA targeting tyrosylprotein sulfotransferases (TPST-1 and TPST-2), then use ACKR2 antibodies to assess how reduced sulfation affects receptor detection and function .

• Site-directed mutagenesis: Generate tyrosine-to-phenylalanine mutants at key sulfation sites and compare antibody binding and functional properties. This approach has revealed that the N-terminal sulfated tyrosine motif is essential for ligand binding by ACKR2 .

• Specialized biochemical techniques: Use antibodies recognizing sulfated tyrosines in combination with ACKR2-specific antibodies. While challenging, this approach can provide direct evidence of modification status.

• Functional correlation: Compare antibody detection with functional assays of chemokine uptake to identify modifications critical for function. Studies have shown that sulfated peptides derived from the ACKR2 N-terminus can effectively compete with the receptor for chemokine binding, while non-sulfated peptides cannot .

What approaches are effective for studying ACKR2 in inflammatory disease models?

When investigating ACKR2 in inflammatory disease models, several methodological approaches have proven valuable:

• Genetic models: ACKR2-deficient mice provide a powerful tool for studying receptor function in vivo. In herpes stromal keratitis (HSK) models, these mice show prolonged clinical signs, increased leukocyte infiltration, and persistent corneal neovascularization when challenged with HSV-1 .

• Quantitative assessment frameworks:

  • For cellular infiltration: Use flow cytometry with ACKR2 antibodies alongside markers for specific immune cell populations (CD11b+ macrophages, CD4+Tbet+ and CD4+RORγt+ T cells)

  • For angiogenesis: Quantify both lymphangiogenesis and vasculogenesis in correlation with ACKR2 expression

• Temporal analysis: Assess ACKR2 expression and function at different time points during disease progression. In HSK, ACKR2 deficiency shows more pronounced effects during later stages (day 14 post-infection) despite similar viral clearance rates early in infection .

• Combinatorial blocking approaches: Use ACKR2 antibodies alongside interventions targeting specific chemokines or their receptors to delineate the relative contribution of different pathways to disease pathology.

What technical considerations are important when developing new ACKR2-targeted therapeutics?

Developing therapeutics targeting ACKR2 requires careful consideration of several factors:

• Antibody engineering approaches:

  • For blocking applications: Target the N-terminal region containing the sulfated tyrosine motif, as this region is essential for ligand binding

  • For detection without functional interference: Select epitopes away from the N-terminal binding domain

• Alternative therapeutic strategies:

  • N-terminal peptide derivatives: Research has shown that sulfated peptides derived from the ACKR2 N-terminus can act as pan-chemokine blockers with potential therapeutic applications in inflammatory pathologies

  • Small molecule inhibitors: These may target the receptor's binding pocket or modulate internalization mechanisms

• Validation methodologies:

  • Functional assays: Chemokine uptake and scavenging assays to confirm target engagement

  • In vivo models: Animal models of inflammation or cancer to assess therapeutic efficacy

  • Combinatorial approaches: Testing ACKR2-targeting strategies in combination with existing therapies, such as immune checkpoint blockade in cancer

• Potential challenges:

  • Proteolytic susceptibility: The bacterial protease staphopain A can cleave the N-terminus of ACKR2 and suppress its ligand internalization activity, suggesting potential challenges in certain inflammatory environments

  • Receptor redundancy: Consider potential compensatory mechanisms through other chemokine receptors

How might ACKR2 antibodies contribute to understanding "cold" vs "hot" tumor microenvironments?

ACKR2 antibodies are increasingly valuable for studying the conversion of immunologically "cold" tumors to "hot" tumors:

• Microenvironmental profiling: Use ACKR2 antibodies in conjunction with chemokine detection to profile the tumor immune landscape. Recent research demonstrates that targeting ACKR2 in melanoma cells increases the release of essential chemokines associated with an inflamed tumor microenvironment .

• Mechanistic investigation: ACKR2 antibodies can help elucidate how chemokine scavenging contributes to immune exclusion in tumors. Genetic targeting of ACKR2 in tumor models has been shown to enhance the infiltration of cytotoxic immune cells and improve response to checkpoint inhibition .

• Therapeutic development: The development of ACKR2-targeting antibodies represents a promising approach for combination immunotherapies. Experiments confirm that ACKR2 inhibition synergizes with anti-PD-1 therapy, potentially overcoming resistance mechanisms .

• Biomarker studies: ACKR2 expression levels may serve as predictive biomarkers for immunotherapy response. Melanoma patient data reveals that even in patients with high CD8 expression, those expressing low ACKR2 survived better than those with high ACKR2 expression .

This emerging research area is particularly significant as it addresses a major challenge in immunotherapy: effectively treating patients with non-inflamed tumors who currently derive limited benefit from immune checkpoint blockade.

What technical challenges exist when purifying and studying ACKR2 peptides released after proteolytic cleavage?

The study of ACKR2 peptides released after proteolytic cleavage presents several technical challenges:

• Detection limitations: Attempts to purify N-terminal peptides released after staphopain A treatment have been challenging, likely due to the low concentrations produced . Similarly, mass spectrometry analysis of truncated ACKR2 species has been unsuccessful, possibly reflecting previously reported difficulties in obtaining mass spectrometry data from ACKR2 .

• Functional assessment approaches: Despite purification challenges, functional effects of proteolytic cleavage can be assessed through:

  • Flow cytometry to measure ligand uptake in cells treated with proteases like staphopain A

  • Fluorescence-based assays adapted for 96-well plate formats to quantify ligand binding and internalization

  • Western blotting with N-terminus-specific antibodies to detect truncated variants

• Methodological adaptations: To overcome these limitations, researchers have employed indirect approaches including:

  • Comparing ligand uptake between intact and protease-treated cells expressing ACKR2

  • Using multiple cell lines (HEK293, CHO) to confirm effects across different expression systems

  • Quantifying multiple parameters simultaneously to build a more complete picture of receptor function

Understanding these technical challenges is important for researchers studying how proteolytic regulation might affect ACKR2 function in inflammatory environments where proteases are abundant.